Zoekresultaten - You searched for Clinical Trials?type=newsArticle

472 results

Go back

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Novel Nanobody to start clinical development in osteoarthritis - ablynx to receive €15 Million milestone payment

BARC and Biogazelle announce collaboration for advanced genetic testing in clinical trials

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Seminar: How Real World Data will change your clinical development to the better

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

argenx reports third quarter 2017 financial results and provides business update

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Celyad Announces Third Quarter 2017 Business Update

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla(TM) platform

Convert Pharmaceuticals secures EUR 13,6 million to develop anti-cancer drugs

argenx reports fourth quarter business update and full year 2017 financial results

Biocartis Selected for Oral Presentation at Cancer Research Meeting

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

argenx appoints Keith Woods as Chief Operating Officer

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

argenx reports first quarter 2018 financial results and provides business update

ProDigest: PROMISE

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

argenx receives milestone payment from strategic collaboration with Shire

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

Celyad Reports First Half 2018 Financial Results and Operational Progress

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

argenx reports first quarter 2017 financial results and provides business update

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Celyad Announces First Quarter 2017 Business Update

TiGenix Launches Global Phase III Trial for Cx601

Kiadis Pharma raises €5 million in private placement with institutional investors

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Celyad announces initiation of the SHRINK trial

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

argenx reports second quarter business update and half-year 2017 financial results

Dosing of First Patient with investigational agent OMO-1

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Mithra Provides Update on Estelle® and Donesta® Studies

UgenTec: announcing our $ 9.3 million Series A funding

UgenTec Announces partnership with Serosep Ltd.

MDxHealth Announces Positive Clinical Updates for ConfirmMDx

MDxHealth's SelectMDx Test Successfully Stratifies Men

OCTIMET Oncology NV awarded €1.077 million R&D grant from VLAIO

argenx receives first preclinical milestone payment in AbbVie collaboration

ThromboGenics Achieves Important Milestone in the Development of THR-149

argenx files registration statement for a proposed public offering in the United States

argenx announces results of Annual General Meeting 2017

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

argenx announces launch of proposed initial public offering in the United States

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

argenx announces size of initial public offering in the United States increased to 5 million ADSs

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Cochlear acquires exclusive licence to Artificial Intelligence assistant

argenx to Present at JMP Securities Life Sciences Conference

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

argenx to Present at Wedbush PacGrow Healthcare Conference

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116

ABL acquisition extends Ardena’s early-phase offering

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Pharmacokinetics in Drug Development - 2017

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Bridging Preclinical and Clinical Development

ThromboGenics Business Update - Q3 2017

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017

Galapagos moving forward in CF programs at NACFC 2017

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

ThromboGenics Strengthens Leadership Team

Bone Therapeutics Business Update for Third Quarter 2017

argenx to Present at Upcoming Investor Conferences

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Promethera Biosciences Provides Update on Executive Management Team

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

argenx announces launch of proposed public offering in the United States

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

Bone Therapeutics Launches Equity Placement

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

Patient centricity in Clinical Research

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Galapagos - Update on progress in cystic fibrosis programs

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Biocartis announces 2017 results and 2018 outlook

CMAST supports Rejuvenate Biomed in their search for ways to impact the ageing process

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Argenx to Present at Cowen & Company 38th Annual Health Care Conference

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Promethera Biosciences Announces Updates to its Board of Directors

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Galapagos announces ISABELA Phase 3 program in IPF

Bone Therapeutics Reports Full Year 2017 Results

Biocartis Q1 2018 business update

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Bone Therapeutics Business Update for First Quarter 2018

ThromboGenics Business Update - Q1 2018

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Webinar: A comprehensible jumpstart towards gcp computer system validation anno 2018

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Gilead and Galapagos announce results with filgotinib in the phase 2 equator study in psoriatic arthritis and progression into phase 3 for the selection study in ulcerative colitis

argenx selected for BEL 20 Index

argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018

Bone Therapeutics announces results of Annual General Meeting

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

argenx receives second preclinical milestone payment under its development agreement with AbbVie

Galapagos: Topline results of PELICAN trial and update on triple combo development plans

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study

argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

argenx to Present at 2018 Wedbush PacGrow Healthcare Conference

NEW EARLY PHASE CLINICAL TRIALS PARADIGM - 6TH BIOPHARM DAY SEMINAR

Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China

ThromboGenics becomes "Oxurion"

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Website

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

argenx announces launch of proposed public offering in the United States

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of DME

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

RegMed

Bootcamp in Entrepreneurial Innovation in Orphan Diseases

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Biocartis Group NV: Biocartis Q1 2017 Business Update

Galapagos reports first quarter 2017 results

Celyad initiates second dose escalation in THINK trial in first US patient

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Biocartis Group NV: Biocartis announces its new CEO

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Bone Therapeutics Business Update for First Quarter 2017

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

SLims by Genohm integrated with Pathomation’s PMA.core

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Smart Implant & (Bio-)medical Imaging Platform Meeting

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

TiGenix announces final equity payment for cardiac platform acquisition

Symposium on Liquid Biopsies & Cancer

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development

TiGenix opens US headquarters in Cambridge, MA

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

SelectMDx to be Distributed Across Middle East by IPS Genomix

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

QBD Webinar on validation of mobile apps

Celyad announces new agreements with Celdara medical and Dartmouth College

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

ConfirmMDx Study Provides Further Validation of Epigenetic Risk Profile

Celyad Reports First Half 2017 Financial Results and Operational Progress

Bone Therapeutics announces H1 results for 2017

ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB

Biocartis announces H1 2017 results

ThromboGenics Business Update - H1 2017

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

TiGenix strengthens US operations with senior appointments

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

ONTOFORCE and akcelis collaborate to create and share infographics

Ablynx files registration statement for a proposed global offering

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Scientists pinpoint surprising origin of melanoma

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Ablynx announces launch of proposed global offering

Newly described process in Parkinson’s protein as a potential new therapy route

Ablynx - Notice in Relation to the Convertible bonds due May 2020

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Ablynx closes $200 Million Initial Public Offering in the United States

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

MDxHealth Nine Month Trading Update

The Adecco Group Announces the Acquisition of CMAST

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Press Release - Life Sciences & Biotechnology

Ablynx to present at the 36th annual J.P. Morgen Healthcare conference

Imec’s SWEET study Collects World’s Largest Dataset on Stress Detection

VIB, CD3 and Galapagos NV enter into a license deal for the development of MALT1 inhibitors

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Scientists discover how treating eczema could also alleviate asthma

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Ablynx appoints dr. Robert Friesen as Chief Scientific Officer

Sanofi to acquire Ablynx for €3.9 Billion

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Ablynx announces 2017 full year results

MDxHealth financial results

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

VIB Plant-derived volatiles may serve as future antifungals

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

MDxHealth Provides First Quarter 2018 Business Update

Ardena acquires Syntagon and strengthens API offering

Do you have to become officially a BIOBANK under the new Belgian law?

CoBioRes receives a € 1.7M grant from VLAIO to support its tetrapeptide prodrug research for treatment of Triple Negative Breast Cancer

MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Mithra successfully raises eur 77.5 million

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

CMAST attends the 2nd General Assembly of RESCEU; a European project focusing on the battle against RSV (June 21st-22nd, Oxford - UK)

flanders.bio provides you with insights in the vibrant life sciences sector

Biogazelle appoints Armin Winands as new CEO

Ardena expands nanomedicine capabilities

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

Galapagos: Publication of the annual report

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder

Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager

TiGenix reports 2016 full year results

Galapagos increases share capital through warrant exercises

Symposium on Sepsis

Specialized blood vessels enhance tumor-fighting immunotherapy

Galapagos raises $338 million gross proceeds in a U.S. public offering

Galapagos announces launch of proposed public offering

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Biogazelle offers unique mRNA sequencing on plasma

Biocartis Group NV: Disclosure of a transparency notification

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Galapagos announces capital increase

Metastatic breast cancers: Characterising the profile of metastases for improved treatment

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Nieuws van de dag - 27/04/2017

ONTOFORCE and Ghent University launch a new innovative ‘text mining’ project

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

VIB: A new unexpected key player in melanoma development identified

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

MDxHealth Trading Update: January to April 2017

Pauwels Consulting neemt Vandycke & Partners en Mediconsult over

Genohm at Pathology Informatics Summit 2017 in Pittsburgh

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

ThromboGenics Business Update - Q1 2017

Biocartis Group NV: Results of the annual shareholders' meeting held on 12 May 2017

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Galapagos to hold Annual R&D Update 2017 on 20 June

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Galapagos creates new warrant plan

argenx announces full exercise of underwriters' option to purchase additional ADSs

Innovative software Moon autonomously diagnoses rare diseases within minutes

argenx announces closing of NASDAQ IPO

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Celyad obtains additional US patent for cancer treatment

Nieuws van de dag- 30/05/2017

Cell Death and Immunity in Disease: from molecules to translational medicine

Biocartis wins prestigious Galenus Prize with its Idylla(TM) NRAS-BRAF Mutation Test for colorectal cancer

TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York

Biocartis Group NV: Disclosure of a transparency notification

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

ThromboGenics to Present the Industry Pipeline of DME Treatments

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Services

Biocartis launches CE-marked IVD test for lung cancer

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Daily Newsflash- 14/06/17

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

Celyad publishes additional pre-clinical data in support of THINK trial

Mithra Successfully Raises €26.1 Million

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Expertise

Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA

flanders.bio strenghtens its team with the appointment of 3 Programme Managers

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Bone Therapeutics Strengthens Board of Directors

UgenTec moves into PCR middleware, partners with Haman Laborautomation

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

TiGenix: Transparency Information

ConfirmMDx Featured in OncologyLive Magazine

MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

Immunity for Health 2017

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Mithra: Recruitment Completed in Estelle® Population PK Substudy

UgenTec receives €50.000 grant by European Union

Bone Therapeutics Notice of Half Year 2017 Results

Ablynx announces 2017 half year results and year-to-date business update

Press Release - Life Sciences & Biotechnology

OLVZ Aalst User Experience Day

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

MDxHealth Announces First Half 2017 Financial Results

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

TiGenix obtains commercial production license for expanded manufacturing facility

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

MDxHealth Prepares for Growth with Executive Team Expansion

Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017

flanders.bio - CMAST Partner Day: Realizing Life Science Innovation with Impact

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Ardena launches following Pharmavize and Crystallics merger

Mithra announces 2017 half year results

Biocartis Group NV: Disclosure of a transparency notification

Galapagos werft aan

Life sciences meets micro-nanoelectronics: zooming in on MEDICAL DEVICES

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

TiGenix to participate and present at key investor and business development meetings

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Dutch Life Sciences conference

Biocartis Group NV: Disclosure of outstanding voting securities

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Ablynx prices $200 million Initial Public Offering in the United States

MyCartis appoints Philippe Stas as CEO

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

TiGenix strengthens European IP protection around lead development program Cx601

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

TiGenix announces partial conversion of bonds

Press Release - Life Sciences & Biotechnology

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Biocartis Group NV: Disclosure of a transparency notification

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Galapagos increases share capital through warrant exercises

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Biocartis successfully raises EUR 80 million in an equity placement

Biocartis Group NV: Disclosure of a transparency notification

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Press Release - Life Sciences & Biotechnology

Galapagos to enter NASDAQ Biotech Index

Galapagos NV - Transparency notification

reMYND enters into license agreement with Novo Nordisk

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Bone Therapeutics Provides Update on Equity Placement

Galapagos Transparency notification

Biocartis Group NV: Disclosure of outstanding voting securities

MDxHealth Announces Lowering of 2017 Guidance

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Takeda announces its intention to acquire TiGenix

Galapagos - Positive topline results with GLPG1972 in osteoarthritis patients

Biocartis Group NV: Disclosure of a transparency notification

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Biocartis - Disclosure of a transparency notification

TiGenix - Transparency Information

Biocartis Group NV: Disclosure of a transparency notification

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

new England biolabs® and Bluebee partner to deliver an end-to-end data analysis solution for Nebnext direct® target enrichment

Disclosure of a transparency notification

MDxHealth contract SelectMDx with Roman Hospital

Biocartis Establishes R&D Center in the US

Bone Therapeutics announces private placement of convertible bonds

Networking

Galapagos publication of the annual report and invitation to the annual shareholders' meeting

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Biocartis Group NV: Biocartis announces publication of its 2017 annual report

Biocartis Group NV: Disclosure of outstanding voting securities

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Bone Therapeutics Notice of Full Year 2017 Results

Galapagos creates new warrant plan

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Agilent Technologies to Enhance Lab Informatics with Acquisition of Genohm

Bone Therapeutics Information on the total number of voting rights and shares

Bone Therapeutics: preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting

Call for candidacies for the Board of Directors of flanders.bio

Biocartis: Results of the annual shareholders' meeting held on 11 May 2018

Promethera Biosciences Establishes Branch Office in Tokyo

GST raises EUR 5 million to develop veterinary stem cell products

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Press Release - Life Sciences & Biotechnology - 23/05/2018

Bone Therapeutics: Information on the total number of voting rights and shares

Galapagos Transparency notification

Galapagos increases share capital through warrant exercises

The first veterinary stem cell product recommended for approval in Europe becomes a reality

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Biocartis launches innovative Idylla(TM) MSI Assay

Microbiome pioneer S-Biomedic secures investment and collaboration with global skin care company beiersdorf

Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)

Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

ISTA Congress London

Bone Therapeutics Notice of Half Year 2018 Results

Press Release - Life Sciences & Biotechnology - 10/08/2018

Innovation Platforms & Projects

Excited About Your Story: Tell it like a TED Pro

Why Ya Buggin’ Out? Regulatory Hurdles and Other Obstacles on the Path to Microbiome Market

Start with the end in Mind – Healthcare Market Access in the Digital Age

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response

Bone Therapeutics: Information on the total number of voting rights and shares

Biocartis Creates New Warrant Plan

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Galapagos raises $300 million gross proceeds in a U.S. public offering

Immunity for Health

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million

Galapagos issues new shares as result of public offering

Go back